论文部分内容阅读
膀胱癌绝大多数(90%以上)为移行细胞癌,并以浅表性(Ⅰ—Ⅱ级、O—A 期)膀胱移行细胞癌为最常见。此种肿瘤手术后的再发率达30—80%。根据文献报道:动物实验及临床报告均表明卡介苗膀胱内灌注可有效地防止和减少浅表性膀胱移行细胞癌的术后再发。至今,膀胱内卡介苗免疫治疗是预防浅表性膀胱移行细胞癌术后再发最成功的方法。现综述如下:动物实验1982年Pang 等用小白鼠作实验,观察卡介苗对肿瘤生长的预防和抑制作用。他们随机将8—12周的CEH/HeN 雌小白鼠分为3组。1组动物19只单纯接种肿瘤细胞(MBT
The vast majority (more than 90%) of bladder cancers are transitional cell carcinomas, with superficial (I-II, O-A) bladder transitional cell carcinoma being the most common. The recurrence rate after such tumor surgery reaches 30-80%. According to reports in the literature: animal experiments and clinical reports have shown that intravesical instillation of BCG can effectively prevent and reduce postoperative recurrence of superficial bladder transitional cell carcinoma. Up to now, intravesical BCG vaccine is the most successful method to prevent the recurrence of superficial bladder transitional cell carcinoma. Now summarized as follows: Animal experiments In 1982 Pang et al. used mice as an experiment to observe the preventive and inhibitory effects of BCG on tumor growth. They randomly divided 8-week-old CEH/HeN mice into 3 groups. 19 animals in one group were inoculated with tumor cells (MBT